Leerink Swann Starts Salix Pharmaceuticals (SLXP) at Market Perform; N-T Catalyst Absent, Long-Term Fundamentals Intact
Tweet
Share
E-mailGet Alerts SLXP Hot Sheet
Price: $172.81 --0%
Rating Summary:
7 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Rating Summary:
7 Buy, 14 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Join SI Premium – FREE
Leerink Swann initiates coverage on Salix Pharmaceuticals (NASDAQ: SLXP) with a Market Perform. PT $47.00.
Analyst, Jason M. Gerberry, said, "With FDA regulatory uncertainty around Relistor and a lack of near-term catalysts, we view SLXP shares as fairly priced...Consensus ests for Xifaxan already incorporate bullish assumptions."
"Risk/reward looks better from a takeout perspective. As highlighted by our Pharma Team (AstraZeneca (NYSE: AZN)), SLXP could be a potential acquisition target for a big pharma with a revenue cliff like AZN. It is worth noting that (1) SLXP would be immediately accretive for AZN, but less than several other potential target."
For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $41.92 yesterday.
Analyst, Jason M. Gerberry, said, "With FDA regulatory uncertainty around Relistor and a lack of near-term catalysts, we view SLXP shares as fairly priced...Consensus ests for Xifaxan already incorporate bullish assumptions."
"Risk/reward looks better from a takeout perspective. As highlighted by our Pharma Team (AstraZeneca (NYSE: AZN)), SLXP could be a potential acquisition target for a big pharma with a revenue cliff like AZN. It is worth noting that (1) SLXP would be immediately accretive for AZN, but less than several other potential target."
For an analyst ratings summary and ratings history on Salix Pharmaceuticals click here. For more ratings news on Salix Pharmaceuticals click here.
Shares of Salix Pharmaceuticals closed at $41.92 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Starts Faeth Therapeutics (FTH) at Buy
- Baird Starts Eaton Corporation (ETN) at Outperform
- Keefe, Bruyette & Woods Resumes Bank of Nova Scotia (BNS:CN) (BNS) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
